Updated national cholesterol guidelines issued by the American Heart Association and the American College of Cardiology expand statin eligibility to an estimated 21.5 million more U.S. adults. Published in July 2026, the framework shifts cardiovascular prevention toward earlier, lifelong risk management using the PREVENT risk calculator and lower LDL cholesterol targets.
A major revision to U.S. blood cholesterol guidance substantially expands the population recommended for primary prevention statin therapy, focusing heavily on younger and lower-risk individuals. The recommendations, released jointly by the American College of Cardiology, the American Heart Association, and nine partnering medical societies, replace the previous 2018 guidelines with a framework that emphasizes long-term risk reduction over decades rather than short-term 10-year windows.
Under the updated criteria, the total number of American adults ages 30 to 79 eligible for statins reaches about 87.5 million people, or nearly 57% of the studied population, according to research published in JAMA. While the guidance does not mean every newly eligible person should immediately start taking medication, it fundamentally alters how clinicians evaluate cardiovascular risk early in life.
Expansion to Younger Adults and Lower-Risk Categories
The updated guidelines expand the age range for routine cardiovascular risk assessment from adults aged 40 to 75 down to ages 30 to 79. By incorporating 30-year risk projections for younger adults, the guidelines capture individuals whose decade-by-decade risk appears low primarily because of their age, despite decades of accumulating low-density lipoprotein cholesterol in their artery walls.
Before the new guidelines, people who were flagged with high cholesterol in their 30s and 40s tended to be recommended to focus on diet and exercise and were not recommended medication — unless the patient already had heart disease or other factors that made them particularly high-risk, like diabetes,
researchers noted in analyses examining the shift.
The newly eligible population tends to be younger and at lower short-term risk, exhibiting an average predicted 10-year risk of 3.1%, compared with 6.1% for those who qualified under the older criteria. At the same time, treatment thresholds for bad cholesterol have been lowered to 70 mg/dL for most patients without a history of cardiovascular events and to 55 mg/dL for high-risk patients.
Adopting the PREVENT Calculator and Advanced Biomarkers
A core update in the management of dyslipidemia is the recommendation to use the Predicting Risk of Cardiovascular Disease EVENTs (PREVENT) equations rather than older assessment tools. Designed for adults ages 30 to 79 without known atherosclerotic cardiovascular disease, the PREVENT tool estimates both 10-year and 30-year risks using routine checkup data such as blood pressure, cholesterol levels, kidney function, and blood sugar.
Studies published alongside the guidelines highlight a significant gap between the new LDL targets and actual cholesterol levels across the country. Researchers evaluating national survey data found that about one-third of adults without a history of heart disease had LDL levels above the new recommended goals, with roughly 76% of those individuals receiving no cholesterol-lowering medication.
Medical societies stress that lifestyle optimization—including maintaining a healthy weight, regular physical activity, avoiding tobacco products, and prioritizing sleep—remains the essential first step before clinicians consider adding lipid-lowering therapies earlier in life.